The combination of LAG-3 inhibition with PD-1 blockade (e.g., relatlimab plus nivolumab) has demonstrated superior clinical efficacy in melanoma, sustaining T-cell activity against tumour cells while impeding immune escape mechanisms [29]. Here, PDCD1 is linked to melanoma.